Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Karyopharm Therapeutics ( (KPTI) ) has shared an update.
On January 12, 2026, Karyopharm reported preliminary unaudited financial results indicating it expects approximately $33 million in total revenue for the fourth quarter of 2025 and about $145 million for full-year 2025, including $32 million and $115 million, respectively, in U.S. XPOVIO net product revenue. The company ended 2025 with roughly $64 million in cash, cash equivalents, restricted cash and investments, and, along with anticipated product and license revenue, believes it can fund operations into the second quarter of 2026, supported by strategic financings that extended its cash runway beyond the upcoming Phase 3 SENTRY myelofibrosis readout. Operationally, Karyopharm completed enrollment of the Phase 3 SENTRY trial in myelofibrosis in September 2025, continued global expansion and steady demand for XPOVIO in a competitive multiple myeloma market, advanced Phase 2 and Phase 3 selinexor programs in myelofibrosis, and refined the design and enrollment of its Phase 3 XPORT-EC-042 endometrial cancer trial, setting up 2026 as a catalyst-heavy year with two major Phase 3 data readouts that could materially influence its position in oncology and long-term value for stakeholders.
The most recent analyst rating on (KPTI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.
Spark’s Take on KPTI Stock
According to Spark, TipRanks’ AI Analyst, KPTI is a Neutral.
Overall score is constrained primarily by weak financial performance (losses, negative equity, and negative free cash flow). Technical momentum is a notable positive with the stock trading above key moving averages and a positive MACD, and the earnings call added support via trial progress and extended runway, but valuation remains challenged due to ongoing losses and no dividend data.
To see Spark’s full report on KPTI stock, click here.
More about Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. Its lead product, XPOVIO (selinexor), is marketed primarily for multiple myeloma, while the company is also advancing selinexor in late-stage trials for myelofibrosis and endometrial cancer, targeting large oncology markets where there is significant unmet medical need.
Average Trading Volume: 196,062
Technical Sentiment Signal: Sell
Current Market Cap: $149.6M
For an in-depth examination of KPTI stock, go to TipRanks’ Overview page.